Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Publisher Name :
Date: 15-Dec-2013
No. of pages: 89

GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.

Scope


  • A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms.

  • In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy.

  • A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets.

  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints.

  • Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.

  • Discussion of the drivers and barriers for market growth.

  • In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006.


Reasons to buy

  • Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies.

  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.

  • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics.

  • Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs.

  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market.

Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.7 Treatment Options 13
2.7.1 Chemotherapy 13
2.7.2 Targeted Therapies 14
2.7.3 Resistance to Pharmacological Therapies 15
2.7.4 Treatment Guidelines 15

3 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Marketed Products 18
3.1 Avastin (Bevacizumab) - Hoffman La Roche 18
3.2 Erbitux (Cetuximab) - Bristol-Myers Squibb, Eli Lilly, and Merck KGaA 19
3.3 Vectibix (Panitumumab) - Amgen and Takeda 21
3.4 Heat Map for Marketed Products 22
3.5 Conclusion 24

4 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Developmental Pipeline 25
4.1 Overall Pipeline 25
4.2 Molecular Targets and Mechanisms of Action 27
4.3 Clinical Trials 28
4.3.1 Failure Rate 28
4.3.2 Clinical Trial Size 29
4.3.3 Duration 32
4.3.4 Primary Endpoints 33
4.4 Conclusion 35
4.5 Key Late-Stage Pipeline Products 35
4.5.1 IMC-1121B (Ramucirumab) - Eli Lilly and Company 35
4.5.2 Xilonix - XBiotech 36
4.5.3 MetMAb (Onartuzumab) - Hoffmann-La Roche 36
4.5.4 Anti-DR5 MoAb (Tigatuzumab) - Daiichi Sankyo 36
4.5.5 MK0646 (Dalotuzumab) - Merck 37
4.5.6 AMG-655 (Conatumumab) - Amgen 37
4.6 Conclusion 37

5 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Market Forecast to 2019 38
5.1 Global 39
5.1.1 Treatment Usage Patterns 39
5.1.2 Market Size 40
5.2 North America 41
5.2.1 US 41
5.2.2 Canada 43
5.3 Europe 44
5.3.1 Treatment Usage Patterns 44
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Size 47
5.4 Japan 48
5.4.1 Treatment Usage Patterns 48
5.4.2 Market Size 49
5.5 Drivers and Barriers 49
5.5.1 Drivers 49
5.5.2 Barriers 50

6 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Deals and Strategic Consolidations 52
6.1 R&D Licensing Agreements 52
6.1.1 Key Licensing Deals 55
6.2 Co-Development Agreements 57
6.2.1 Key Co-Development Agreements 58

7 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Appendix 59
7.1 Market Definitions 59
7.2 Abbreviations 59
7.3 References 62
7.4 Sources for Heat Map 66
7.5 All Pipeline Products, by Stage of Development 67
7.5.1 Discovery 67
7.5.2 Preclinical and IND/CTA-filed 68
7.5.3 Phase I 73
7.5.4 Phase II 76
7.5.5 Phase III and Pre-registration 81
7.5.6 Undisclosed 82
7.6 Tabular Forecast Data 83
7.6.1 Global 83
7.6.2 US 83
7.6.3 Canada 83
7.6.4 UK 83
7.6.5 France 84
7.6.6 Germany 84
7.6.7 Italy 84
7.6.8 Spain 84
7.6.9 Japan 85
7.7 Research Methodology 85
7.7.1 Coverage 85
7.7.2 Secondary Research 85
7.7.3 Primary Research 86
7.7.4 Therapeutic Landscape 86
7.7.5 Epidemiology-Based Forecasting 86
7.7.6 Market Size by Geography 88
7.7.7 Geographical Landscape 89
7.7.8 Pipeline Analysis 89
7.8 Contact Us 89
7.9 Disclaimer 89

List of Tables

Table 1: Market for mAbs in Colorectal Cancer, US, Epidemiology, 2008 10
Table 2: Market for mAbs in Colorectal Cancer, US, Diagnosis by Stage, 2009 10
Table 3: Market for mAbs in Colorectal Cancer, US, Five-Year Survival by Stage, 2009 12
Table 4: Market for mAbs in Colorectal Cancer, Global, TNM Staging, 2013 13
Table 5: Market for mAbs in Colorectal Cancer, Sources for Heat Map 66
Table 6: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 67
Table 7: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013 68
Table 8: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 73
Table 9: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 76
Table 10: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 81
Table 11: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013 82
Table 12: Market for mAbs in Colorectal Cancer, Global, Forecast Data, 2012-2019 83
Table 13: Market for mAbs in Colorectal Cancer, US, Forecast Data, 2012-2019 83
Table 14: Market for mAbs in Colorectal Cancer, Canada, Forecast Data, 2012-2019 83
Table 15: Market for mAbs in Colorectal Cancer, UK, Forecast Data, 2012-2019 83
Table 16: Market for mAbs in Colorectal Cancer, France, Forecast Data, 2012-2019 84
Table 17: Market for mAbs in Colorectal Cancer, Germany, Forecast Data, 2012-2019 84
Table 18: Market for mAbs in Colorectal Cancer, Italy, Forecast Data, 2012-2019 84
Table 19: Market for mAbs in Colorectal Cancer, Spain, Forecast Data, 2012-2019 84
Table 20: Market for mAbs in Colorectal Cancer, Japan, Forecast Data, 2012-2019 85

List of Figures

Figure 1: Market for mAbs in Colorectal Cancer, Global, ESMO Treatment Guidelines (Colorectal Cancer at Stage I to III) 16
Figure 2: Market for mAbs in Colorectal Cancer, Global, ESMO Treatment Guidelines (Colorectal Cancer at Stage IV) 17
Figure 3: Market for mAbs in Colorectal Cancer, Global, Sales of Avastin ($bn), 2004-2012 19
Figure 4: Market for mAbs in Colorectal Cancer, Global, Sales of Vectibix ($m), 2006-2012 21
Figure 5: Market for mAbs in Colorectal Cancer, Global, Heat Map of Safety and Efficacy for Marketed Products, 2013 23
Figure 6: Market for mAbs in Colorectal Cancer, Global, Overall Pipeline, 2013 26
Figure 7: Market for mAbs in Colorectal Cancer, Global, Pipeline mAbs by Mechanism of Action and Molecular Target, 2013 27
Figure 8: Market for mAbs in Colorectal Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 28
Figure 9: Market for mAbs in Colorectal Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 29
Figure 10: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Sizes, 2006-2013 30
Figure 11: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013 31
Figure 12: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Durations, 2006-2013 32
Figure 13: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013 33
Figure 14: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Primary Endpoints, 2006-2012 34
Figure 15: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Primary Endpoints, 2006-2012 35
Figure 16: Market for mAbs in Colorectal Cancer, Global, Market Growth and Size, 2012-2019 38
Figure 17: Market for mAbs in Colorectal Cancer, Global, Treatment Patterns, 2012-2019 39
Figure 18: Market for mAbs in Colorectal Cancer, Global, Market Size ($bn), 2012-2019 40
Figure 19: Market for mAbs in Colorectal Cancer, US, Treatment Usage Patterns, 2012-2019 41
Figure 20: Market for mAbs in Colorectal Cancer, US, Market Size ($m), 2012-2019 42
Figure 21: Market for mAbs in Colorectal Cancer, Canada, Treatment Usage Patterns, 2012-2019 43
Figure 22: Market for mAbs in Colorectal Cancer, Canada, Market Size ($m), 2012-2019 44
Figure 23: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Treatment Patterns, 2012-2019 45
Figure 24: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Annual Cost of Therapy, 2012-2019 46
Figure 25: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Market Size ($m), 2012-2019 47
Figure 26: Market for mAbs in Colorectal Cancer, Japan, Treatment Usage Patterns, 2012-2019 48
Figure 27: Market for mAbs in Colorectal Cancer, Japan, Market Size ($m), 2012-2019 49
Figure 28: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 52
Figure 29: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 53
Figure 30: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 54
Figure 31: Market for mAbs in Colorectal Cancer, Global, Co-development Deals Global Network, 2006-2013 57
Figure 32: Market for mAbs in Colorectal Cancer, Global, Co-development Deals by Year and Value, 2006-2013 58
Figure 33: GBI Research Market Forecasting Model 88

  • Anti GM-CSF Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti GM-CSF Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti GM-CSF Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Anti-CD105 Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD105 Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD105 Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acq......
  • Anti-CD152 Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD152 Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD152 Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acq......
  • Anti-CD19 Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD19 Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD19 Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • Anti-CD22 Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD22 Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD22 Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • Anti-CD25 Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD25 Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD25 Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD274 (PD-L1) Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD274 (PD-L1) Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, col......
  • Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD279 (PD-1) Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD279 (PD-1) Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, colla......
  • Anti-CD28 Antibody -Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, "Anti-CD28 Antibody-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD28 Antibody. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs